Published in CMAJ on October 14, 2014
Treatment of hypertension in patients 80 years of age or older. N Engl J Med (2008) 21.04
Effect of lower sodium intake on health: systematic review and meta-analyses. BMJ (2013) 5.78
Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA (2005) 4.64
Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDANA Group. Lancet (1999) 3.81
Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials. BMJ (2013) 3.68
Impact of resistance training on blood pressure and other cardiovascular risk factors: a meta-analysis of randomized, controlled trials. Hypertension (2011) 3.06
The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol (2013) 1.85
The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol (2014) 1.80
The Canadian Hypertension Education Program--a unique Canadian initiative. Can J Cardiol (2006) 1.76
On-treatment diastolic blood pressure and prognosis in systolic hypertension. Arch Intern Med (2007) 1.75
Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs Aging (2001) 1.03
Myocardial perfusion pressure in patients with hypertension and coronary artery disease: implications for DBP targets in hypertension management. J Hypertens (2013) 0.84
Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology (2011) 12.09
Translation of research evidence from animals to humans. JAMA (2006) 4.48
Derivation and validation of an index to predict early death or unplanned readmission after discharge from hospital to the community. CMAJ (2010) 3.60
Intensive and Standard Blood Pressure Targets in Patients With Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis. Arch Intern Med (2012) 3.26
GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone. Hypertension (2011) 3.26
Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet (2011) 3.15
Renal outcome in patients with congenital anomalies of the kidney and urinary tract. Kidney Int (2009) 3.13
Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med (2010) 2.97
Statins and sepsis: multiple modifications at multiple levels. Lancet Infect Dis (2007) 2.84
Validation of a case definition to define hypertension using administrative data. Hypertension (2009) 2.74
Nephrology visits and health care resource use before and after reporting estimated glomerular filtration rate. JAMA (2010) 2.61
Overview of the Alberta Kidney Disease Network. BMC Nephrol (2009) 2.58
Guidelines for the management of chronic kidney disease. CMAJ (2008) 2.54
Rates of treated and untreated kidney failure in older vs younger adults. JAMA (2012) 2.43
Statins: panacea for sepsis? Lancet Infect Dis (2006) 2.32
Translating animal research into clinical benefit. BMJ (2007) 2.25
The short- and long-term impact of multi-disciplinary clinics in addition to standard nephrology care on patient outcomes. Nephrol Dial Transplant (2004) 2.18
Proteinuria and life expectancy. Am J Kidney Dis (2012) 2.16
The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1- blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol (2005) 2.13
Students, stress and coping strategies: a case of Pakistani medical school. Educ Health (Abingdon) (2004) 2.12
Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol (2009) 2.12
Carotid plaque area: a tool for targeting and evaluating vascular preventive therapy. Stroke (2002) 2.10
Shift work and vascular events: systematic review and meta-analysis. BMJ (2012) 2.10
The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy. Can J Cardiol (2005) 2.03
The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol (2007) 2.01
A prospective cohort study found that provider and information continuity was low after patient discharge from hospital. J Clin Epidemiol (2010) 1.95
Pregnancy in CKD stages 3 to 5: fetal and maternal outcomes. Am J Kidney Dis (2007) 1.93
Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis (2005) 1.92
New fibrate use and acute renal outcomes in elderly adults: a population-based study. Ann Intern Med (2012) 1.91
Chronic kidney disease and life expectancy. Nephrol Dial Transplant (2012) 1.90
The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol (2012) 1.86
The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol (2013) 1.85
Associations between acute kidney injury and cardiovascular and renal outcomes after coronary angiography. Circulation (2011) 1.85
Rituximab in children with resistant idiopathic nephrotic syndrome. J Am Soc Nephrol (2012) 1.83
Fistula maturation: doesn't time matter at all? Nephrol Dial Transplant (2005) 1.77
Adenylyl cyclase isoform-selective regulation of vascular smooth muscle proliferation and cytoskeletal reorganization. Circ Res (2006) 1.76
Temporal trends in antihypertensive drug prescriptions in Canada before and after introduction of the Canadian Hypertension Education Program. J Hypertens (2003) 1.76
Validity of administrative database coding for kidney disease: a systematic review. Am J Kidney Dis (2011) 1.73
The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy. Can J Cardiol (2006) 1.67
Biology of arteriovenous fistula failure. J Nephrol (2007) 1.66
Impaired renal function modifies the risk of severe hypoglycaemia among users of insulin but not glyburide: a population-based nested case-control study. Nephrol Dial Transplant (2010) 1.65
New insights into membranous glomerulonephritis: from bench to bedside. Nephrol Dial Transplant (2011) 1.64
Treating arteries instead of risk factors: a paradigm change in management of atherosclerosis. Stroke (2010) 1.63
Validating ICD coding algorithms for diabetes mellitus from administrative data. Diabetes Res Clin Pract (2010) 1.60
Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med (2006) 1.54
Diabetes during diarrhea-associated hemolytic uremic syndrome: a systematic review and meta-analysis. Diabetes Care (2005) 1.53
Cripto-1 activates nodal- and ALK4-dependent and -independent signaling pathways in mammary epithelial Cells. Mol Cell Biol (2002) 1.53
Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy. Clin J Am Soc Nephrol (2012) 1.51
Atheroembolic renal disease. Lancet (2010) 1.50
Outcomes among 3.5 million newly diagnosed hypertensive Canadians. Can J Cardiol (2013) 1.50
A randomized survey of the preference of gastroenterologists for a Cochrane review versus a traditional narrative review. Can J Gastroenterol (2002) 1.49
The 2001 Canadian recommendations for the management of hypertension: Part two--Therapy. Can J Cardiol (2002) 1.49
De novo ACTA2 mutation causes a novel syndrome of multisystemic smooth muscle dysfunction. Am J Med Genet A (2010) 1.49
Canadian Society of Nephrology 2014 clinical practice guideline for timing the initiation of chronic dialysis. CMAJ (2014) 1.48
miR-146a-Mediated extracellular matrix protein production in chronic diabetes complications. Diabetes (2011) 1.47
The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy. Can J Cardiol (2004) 1.46
The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol (2010) 1.44
Trends in antihypertensive drug prescriptions and physician visits in Canada between 1996 and 2006. Can J Cardiol (2008) 1.43
The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy. Can J Cardiol (2009) 1.42
Is therapy of people with chronic kidney disease ONTARGET? Nephrol Dial Transplant (2009) 1.42
Simplified therapeutic intervention to control hypertension and hypercholesterolemia: a cluster randomized controlled trial (STITCH2). J Hypertens (2013) 1.42
Updated national and international hypertension guidelines: a review of current recommendations. Drugs (2014) 1.41
Use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and cardiovascular outcomes in chronic dialysis patients: a population-based cohort study. Arch Intern Med (2012) 1.40
Arteriovenous fistula surgery: an American perspective from Italy. Semin Dial (2006) 1.39
The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol (2011) 1.38
A Nodal- and ALK4-independent signaling pathway activated by Cripto-1 through Glypican-1 and c-Src. Cancer Res (2003) 1.32
Lifetime risk of ESRD. J Am Soc Nephrol (2012) 1.31
Effects of intensive medical therapy on microemboli and cardiovascular risk in asymptomatic carotid stenosis. Arch Neurol (2009) 1.30
Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: Alfa-enolase and borderline antigens. J Proteomics (2011) 1.28
Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut (2013) 1.26
The impact of the Canadian Hypertension Education Programme in its first decade. Eur Heart J (2009) 1.26
Cripto-1: an oncofetal gene with many faces. Curr Top Dev Biol (2005) 1.26
The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol (2008) 1.25